Document is current
Any future updates will be listed below
-
Authors
Okamoto, Akinao https://orcid.org/0000-0002-9607-8536
Kanda, Yoshinobu
Kimura, Shun-ichi
Oyake, Tatsuo
Tamura, Kazuo
,
-
Clinical Trials BETA
Clinical trials referenced in this document:
umin00010411 at UMIN JapanDocuments that mention this clinical trial
Predictive and risk factor analysis for bloodstream infection in high-risk hematological patients with febrile neutropenia: post-hoc analysis from a prospective, large-scale clinical study
https://doi.org/10.1007/s12185-021-03183-x
- License Information
-
More Information
Article History
Received: 11 May 2021
Revised: 19 June 2021
Accepted: 20 June 2021
First Online: 25 June 2021
Declarations
:
: Yoshinobu Kanda received honoraria from Merck Sharp & Dohme, Pfizer, Astellas Pharma, Janssen, Chugai Pharma, Otsuka, Celgene, Sumitomo Dainippon Pharma, Eisai, Novartis, Kyowa Hakko Kirin, Bristol-Myers Squibb, Takeda Pharmaceuticals, Alexion Pharmaceuticals, Shire, Daiichi Sankyo, Ono Pharmaceutical, Nippon Shinyaku, Mochida Pharmaceutical, Mundipharma, Sanofi, and Meiji Seika Kaisha and research funding from Astellas Pharma, Eisai, Otsuka, Kyowa Hakko Kirin, Sanofi, Shionogi, Taiho Pharmaceutical, Chugai Pharma, Nippon Shinyaku, and Pfizer. Shun-ichi Kimura received honoraria from Astellas Pharma, Pfizer, Sumitomo Dainippon Pharma, Merck Sharp & Dohme, Nippon Kayaku, Kyowa Hakko Kirin, Asahi Kasei, Ono Pharmaceutical, Takeda Pharmaceuticals, and Celgene. Tatsuo Oyake received honoraria from Astellas Pharma, Chugai Pharma, Celgene, Kyowa Hakko Kirin, Sumitomo Dainippon Pharma, Bristol-Myers Squibb Japan, and Pfizer and research funding from Kyowa Hakko Kirin, Chugai Pharma, Sionogi, and Bayer. Kazuo Tamura received honoraria from Ono Pharmaceutical, Eisai, Asahi Kasei, and Kyowa Hakko Kirin. All other authors: none to declare.
: This study was approved by the Ethics Review Committee, Fujita Health University and conducted according to the principles of the Declaration of Helsinki (HM19-487).
